



International Alliance for
Biological Standardization

Virtual meeting

September 25-26, 2024

Next Generation Sequencing Webinar

The IABS NGS webinar will give an introduction to Next Generation Sequencing (NGS) technologies and their applications in the viral safety testing package of biological products. It will particularly cover a review of the sources of introducing adventitious viral agent contamination in the biomanufacturing process, reports of cases of contamination with adventitious viral agents, considerations for using NGS as an alternative method for the current adventitious virus detection assays, and an overview of the different steps in the NGS workflow.

The talks and discussions focus on enhancing viral safety of biologics. The webinar will also provide an overview of the Advanced Virus Detection Technologies Working group (AVDTWG) activities and an update of the regulatory landscape from various regions.

The webinar is addressed to all manufacturers and regulators who want to learn about NGS applications for adventitious viral agent detection in biological products following its recent introduction in the ICHQ5A (R2) guideline and the publication for comment of the new EDQM/Ph. Eur general chapter 2.6.41 "High-Throughput Sequencing for the detection of viral extraneous agents."

More information



Free registration
Registration needed
www.iabs.org

Scientific Committee :

- **Arifa S. KHAN**, co-chair
FDA-CBER (FDA), U.S.A.
- **Laurent MALLET**, co-chair, EDQM, France
- **Pieter NEELS**, IABS Human Vaccine
Committee Chair, Belgium
- **Johannes BLÜMEL**, PEI, Germany
- **Noémie DENEYER**, GSK, Belgium
- **Sigrid DE KEERSMAECKER**, Sciensano,
Belgium
- **Blandine DE SAINT-VIS**, Boehringer-
Ingelheim, France
- **Ivana KNEZEVIC**, WHO, Switzerland
- **Carine LOGVINOFF**, Sanofi, France
- **Marie MURPHY**, Eli Lilly, Ireland
- **Siemon NG**, Notch Therapeutics Canada
- **Yoji SATO**, NIHS, Japan
- **Michael WALL**, Health Canada